The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Continue advancing our pipeline candidates, with several key updates in 2025, including CTX112™ in oncology and autoimmune ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

'Mad Money' host Jim Cramer weighs in on stock including: Lincoln Electric, Caesars Entertainment, CRISPR, and Seagate. This ...